Drug Trial Radar · NCT07534592
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Apr 16, 2026
Primary completion
Jan 25, 2027
Study completion Jan 25, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
Conditions
- Healthy Participants
Interventions
ElecoglipronDrug
Elecoglipron will be administered as oral tablet.
AtorvastatinDrug
Atorvastatin will be administered as oral tablet.
RosuvastatinDrug
Rosuvastatin will be administered as oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Maximum observed drug concentration (Cmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- AUCinf of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- AUClast of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- Cmax of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUCinf (R AUCinf) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUClast (R AUClast) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on Cmax (R Cmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Terminal elimination half-life (t1/2λz) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Terminal rate constant (λz) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Time to reach maximum observed concentration (tmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
- Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUCinf (R AUCinf) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUClast (R AUClast) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on Cmax (R Cmax) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- t1/2λz of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- λz of rosuvastatinTime frame: Group 2: Day 1 to Day 76
- tmax of rosuvastatinTime frame: Group 2: Day 1 to Day 76
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.